Skip to main content
SpringerLink
Log in

Bevacizumab in Non-Small Cell Lung Cancer

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Lung cancer continues to be the leading cause of cancer death in Western countries. The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor and chemotherapy is the treatment of choice for most patients with metastatic NSCLC. Platinum-based chemotherapy has long been the standard of care for advanced NSCLC. The formation of new blood vessels (angiogenesis) is needed for the growth and invasiveness of primary tumours, and plays an important role in metastatic growth. Vascular endothelial growth factor (VEGF) has emerged as a key potential target for the pharmacological inhibition of tumour angiogenesis. This review discusses current data and the future potential of bevacizumab, a recombinant humanized monoclonal antibody that binds VEGF, in the treatment of NSCLC.

Results from a phase II study showed that the addition of bevacizumab to the first-line chemotherapy with paclitaxel and carboplatin (CP) may increase the overall survival (OS) and the time to progression in advanced NSCLC. Based on these promising results, a randomized phase III trial compared the combination of bevacizumab with CP versus CP alone in the treatment of advanced non-squamous NSCLC. The combination of CP plus bevacizumab led to a statistically significant increase in median OS and progression-free survival (PFS) compared with CP alone, with a response rate (RR) in the CP arm of 15% compared with 35% in the bevacizumab plus CP arm (p < 0.001). More recently, the randomized AVAIL (Avastin in Lung Cancer) study, which evaluated cisplatin with gemcitabine plus bevacizumab in two different dosages versus chemotherapy alone in 1043 patients with recurrent or advanced non-squamous NSCLC, reported a significant increase of PFS, RR and duration of response for both of the bevacizumab-containing arms. Bevacizumab has also been investigated in combination with erlitonib as second-line treatment in two small early phase trials, with interesting results.

Bevacizumab was generally well tolerated in clinical trials; the main treatment-associated adverse events were neutropenia and haemorrhage, especially in the lung, but also at other sites. Several trials that incorporate bevacizumab in combination with new active drugs in NSCLC are ongoing and should further help to define the place of bevacizumab in the therapy of NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30

    Article  PubMed  Google Scholar 

  2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br J Med 1995; 311: 899–909

    Article  Google Scholar 

  3. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459–65

    PubMed  CAS  Google Scholar 

  4. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18: 122–30

    PubMed  CAS  Google Scholar 

  5. Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer project. J Clin Oncol 1999; 17: 3522–30

    PubMed  Google Scholar 

  6. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210–8

    PubMed  CAS  Google Scholar 

  7. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8

    Article  PubMed  CAS  Google Scholar 

  8. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285–91

    Article  PubMed  CAS  Google Scholar 

  9. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase II study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX326 study group. J Clin Oncol 2003; 21: 3016–24

    Article  PubMed  CAS  Google Scholar 

  10. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330–53

    Article  PubMed  Google Scholar 

  11. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6

    Article  PubMed  CAS  Google Scholar 

  12. Ferrara N, Kerbel RS. Angiogenesis as therapeutic target. Nature 2005; 438: 967–74

    Article  PubMed  CAS  Google Scholar 

  13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42

    Article  PubMed  CAS  Google Scholar 

  14. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–76

    Article  PubMed  CAS  Google Scholar 

  15. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique ‘window’ of opportunity. Cancer Cell 2004; 6: 529–31

    PubMed  CAS  Google Scholar 

  16. Herbst RS, Onn A, Sandler A. Agiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005; 23: 3243–56

    Article  PubMed  CAS  Google Scholar 

  17. Stinchcombe TE, Socinski MA. Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 2007; 26: 3691–8

    Article  PubMed  CAS  Google Scholar 

  18. Trivella M, Pezzella F, Pastorino U, et al. Microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of individual patients data. Lancet Oncol 2007; 8: 488–99

    Article  PubMed  Google Scholar 

  19. Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol 1995; 6: 1059–62

    PubMed  CAS  Google Scholar 

  20. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3: 861–5

    PubMed  CAS  Google Scholar 

  21. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184–91

    Article  PubMed  CAS  Google Scholar 

  22. Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50

    Article  PubMed  CAS  Google Scholar 

  23. Manegold C, Von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapynaive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract no. LBA7514]. Proc Am Soc Clin Oncol 2007; 25: 388s

    Google Scholar 

  24. Patel JD, Hensing TA, Villafor V, et al. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): preliminary results [abstract no. 7601]. Proc Am Soc Clin Oncol 2007; 25: 409s

    Google Scholar 

  25. Davila E, Lilenbaum R, Raez L, et al. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC) [abstract no. 17009]. Proc Am Soc Clin Oncol 2006; 24: 667s

    Google Scholar 

  26. Groen HJ, Smit EF, Dingemans A, et al. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC) [abstract no. 7625]. Proc Am Soc Clin Oncol 2007; 25: 415s

    Google Scholar 

  27. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study [abstract no. 7535]. Proc Am Soc Clin Oncol 2007; 25: 393s

    Google Scholar 

  28. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544–55

    Article  PubMed  CAS  Google Scholar 

  29. Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 2007; 25: 4743–50

    Article  PubMed  CAS  Google Scholar 

  30. A study comparing bevacizumab therapy with or without erlotinib for first-line treatment of non-small cell lung cancer (ATLAS) [ClinicalTrials.gov identifier: NCT00257608]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00257608 [Accessed 2008 Mar 3]

  31. A study of bevacizumab in combination with first-or second-line therapy in subjects with treated brain metastases due to non-squamous NSCLC (PASSPORT) [ClinicalTrials.gov identifier: NCT00312728]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00312728 [Accessed 2008 Mar 3]

  32. A study of bevacizumab plus carboplatin and paclitaxel in subjects with advanced, previously untreated, squamous non-small cell lung cancer (BRIDGE) [ClinicalTrials.gov identifier: NCT00318136]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00318136 [Accessed 2008 Mar 3]

  33. A study to evaluate the efficacy of bevacizumab in combination with tarceva for advanced non-small cell lung cancer [Clinical-Trials.gov identifier: NCT00130728]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00130728 [Accessed 2008 Mar 3]

  34. A study of avastin (bevacizumab) in combination with platinum-based chemotherapy in patients with advanced or recurrent squamous non-small cell lung cancer [ClinicalTrials.gov identifier: NCT00404703]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00404703 [Accessed 2008 Mar 3]

  35. Bevacizumab, paclitaxel, carboplatin, and radiation therapy to the chest in treating patients with locally advanced non-small cell lung cancer [ClinicalTrials.gov identifier: NCT00369551]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00369551 [Accessed 2008 Mar 3]

  36. Multimodality treatment for patients with resectable non-small cell lung cancer (NSCLC) —BEACON study: Bevacizumab and Chemotherapy for Operable NSCLC [ClinicalTrials.gov identifier: NCT00130780]. ClinicalsTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00130780 [Accessed 2008 Mar 3]

  37. Sandler AB, Johnson DH, Brahmer J, et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC) [abstract no. 7068]. Proc Am Soc Clin Oncol 2006; 24: 381s

    Google Scholar 

Download references

Acknowledgements

The authors have declared that they have received no funding to assist in the preparation of this review and have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Viale Pieraccini 17, Florence, 50139, Italy

    Francesco Di Costanzo, Francesca Mazzoni, Marinella Micol Mela, Lorenzo Antonuzzo, Daniele Checcacci & Matilde Saggese

  2. Unit of Internal Medicine and Oncology, General Hospital, Azienda Sanitaria Locale 4, Orvieto, Italy

    Federica Di Costanzo

Authors
  1. Francesco Di Costanzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Mazzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marinella Micol Mela
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lorenzo Antonuzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniele Checcacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matilde Saggese
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Federica Di Costanzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Di Costanzo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Costanzo, F., Mazzoni, F., Mela, M.M. et al. Bevacizumab in Non-Small Cell Lung Cancer. Drugs 68, 737–746 (2008). https://doi.org/10.2165/00003495-200868060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868060-00002

Keywords

Search

Navigation